<DOC>
	<DOCNO>NCT02367859</DOCNO>
	<brief_summary>This pilot clinical trial study dabrafenib treat patient ameloblastoma specific mutation ( change ) BRAF gene . Dabrafenib may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Dabrafenib Treating Patients With BRAF Mutated Ameloblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To observe response rate ameloblastoma dabrafenib 6 week . SECONDARY OBJECTIVES : I. Feasibility safety patient population . II . Response assess pathologically . III . Two main histologic assay treatment response use : tumor necrosis phosphorylated-mitogen-activated protein kinase kinase 1 ( MEK ) , phosphorylated-extracellular signal-regulated kinase ( ERK ) , Ki-67 level measure immunohistochemistry . OUTLINE : Patients receive dabrafenib orally ( PO ) twice daily ( BID ) every 12 hour 6 week absence disease progression unacceptable toxicity . Patients whose disease judge amenable resection continue dabrafenib indefinitely long tumor progression . After completion study treatment , patient follow least 4 week .</detailed_description>
	<mesh_term>Ameloblastoma</mesh_term>
	<mesh_term>Adamantinoma</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Histological diagnosis ameloblastoma ; stage eligible ; patient must evaluable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criteria BRaf protooncogene , serine/threonine kinase ( BRAF ) V600E know dabrafenib sensitive BRAF mutation tumor Clinical Laboratory Improvement Amendments ( CLIA ) certify lab ; may include , example , Sanger sequencing , SNaPshot platform , immunohistochemistry , Foundation One test , etc . ) Life expectancy &gt; 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Absolute neutrophil count ( ANC ) &gt; 1.5 x10^9/L Platelet ( PLT ) &gt; 99 x 10^9/L Hemoglobin &gt; 8 g/dL Total bilirubin ( Tbili ) &lt; 1.6 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &lt; 2.6 x ULN Alkaline phosphatase ( alk phos ) &lt; 2.6 x ULN Serum creatinine &lt; 1.6 x ULN creatinine clearance &gt; 50 ml/min Ability understand willingness sign write informed consent document Patients childbearing potential must agree use effective contraception least 6 month treatment dabrafenib Able swallow retain oral medication must clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel Left ventricular ejection fraction equal great normal No prior treatment agent target BRAF mutant tyrosine kinases radiation target lesion Invasive malignancy ameloblastoma within 3 year , exclude curatively treat basal cell carcinoma , highly curable cancer early stage cutaneous squamous cell carcinoma ( T1 NO ) cervical carcinoma situ ( CIS ) , early stage prostate cancer , thyroid cancer breast cancer Uncontrolled hypertension , chronic heart failure ( CHF ) , major medical illness Prior allergic reaction attribute compound similar chemical biologic composition dabrafenib Concomitant use strong inhibitor ( e.g. , ketoconazole , nefazodone , clarithromycin , gemfibrozil ) strong inducer ( e.g. , rifampin , phenytoin , carbamazepine , phenobarbital , St John 's wort ) cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) cytochrome P450 , family 2 , subfamily C , polypeptide 8 ( CYP2C8 ) Concomitant use proton pump inhibitor , H2receptor antagonists , antacid Known glucose6phosphate dehydrogenase ( G6PD ) deficiency Pregnant nursing patient ; woman childbearing potential must negative pregnancy test within 14 day enrollment Electrocardiogram ( EKG ) QTcB ( Bazett 's formula ) &gt; 480 m do within 14 day enrollment Interstitial lung disease pneumonitis A history retinal vein occlusion ( RVO ) Congestive heart failure NYHA class III worse ( Marked limitation physical activity . Comfortable rest . Less ordinary activity cause fatigue , palpitation , dyspnea . ) A history acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ameloblastoma</keyword>
	<keyword>BRAF</keyword>
	<keyword>odontogenic cancer</keyword>
	<keyword>adamantinoma</keyword>
</DOC>